Pfizer began marketing a Remicade biosimilar in the US in October, which was originally developed by Samsung Bioepis’ South Korean rival Celltrion. Like Pfizer’s Remsima, Renflexis will not be ...

This means biosimilar drugs, such as Hospira's Inflectra and Napp's Remsima will gain ground on established biologics such as MSD's Remicade, Pfizer's Enbrel and AbbVie's Humira. Biologics are now ...

Celltrion developed and manufactured the world’s first monoclonal antibody biosimilar, followed by the first and only subcutaneous (SC) formulation infliximab, ‘Remsima ® SC’, which was ...